entertainment -WSS

entertainment

author：comprehensive 2025-09-30 12:11:34 - browse：56771

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： At ASCO, AstraZeneca reports strong data for breast cancer drug

WSS

Let's speed up science by embracing open access publishing

Cord blood banking comes at a high cost to babies

HIV drugs protect against transmission, even in unprotected sex

What is microchimerism and how does it affect maternal health?

Intellia reports positive results for its CRISPR

Lung cancer screening guidelines updated for cigarette smokers

focus

entertainment

focus

Supreme Court strikes down use of affirmative action

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Novavax promises a turnaround & Lilly roils the obesity market

With trial win, GSK could get blood cancer drug back on market

As demand for Covid shots wanes, Moderna seeks its next success

At ASCO, AstraZeneca reports strong data for breast cancer drug

Hepatitis C has a cure — but many Americans still lack access to it

Explaining an after

ChatGPT in medicine: STAT answers readers' burning questions

How to increase colonoscopy rates? Looks like an AI can help

focus

ASCO: Palliative care found as helpful given virtually as in person

The health care issue Democrats can’t solve: hospital reform

Kidney transplant patients stopped immunosuppressants in trial

Readout LOUD podcast: ESMO highlights & Roivant's big deal

After Sarepta trial failure, Duchenne families brace for more debate

Woman returns to dialysis after doctors remove transplanted pig kidney

Wikipedia

hotspot

entertainment

focus